DERM on Nasdaq

Journey Medical Corp

American pharmaceutical preparations company based in Scottsdale. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

$61.2MRevenue, fiscal 20252
-$11.4MNet income, fiscal 20252

Compare with Tango Therapeutics (United States), Nuvation Bio Inc. or Fortress Biotech, or pick any stock.

  • TickerDERM on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersScottsdale, Arizona1
  • Incorporated inDE3
  • Business address9237 E Via De Ventura Blvd., Suite 105, Scottsdale, Az 852583
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-13.3%Operating margin2
-18.7%Net margin2
11.1%Revenue growth, 20252
-35.9%Return on equity2
0.79×Debt to equity2

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Qbrexza brought in 41% of the revenue Journey Medical Corp broke down this way in fiscal 2025.

  1. Qbrexza$25.0M241%down 0% from 2024
  2. Emrosi$14.7M224%
  3. Accutane$12.9M221%down 34% from 2024
  4. Foam franchise products Amzeeq & Zilxi$5.9M210%down 12% from 2024
  5. Other (Legacy)$2.7M24%down 31% from 2024
Products and services by year
Products and services20242025
Qbrexza$25.1M$25.0M
Emrosi$14.7M
Accutane$19.4M$12.9M
Foam franchise products Amzeeq & Zilxi$6.7M$5.9M
Other (Legacy)$4.0M$2.7M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue32¢$20.9M
  • Research and development1¢$480.0K
  • Selling, general and admin67¢$44.4M
  • Income tax0¢$60.0K

Out of $61.2M in revenue.2 The company lost money this year.

Financial statements

Revenue45672$61.2M in 2025+38% since 2020
0$20.0M$40.0M$60.0M$80.0M2020: $44.5M$44.5M20202021: $63.1M$63.1M2021+42%2022: $71.0M$71.0M2022+12%2023: $59.7M$59.7M2023−16%2024: $55.1M$55.1M2024−8%2025: $61.2M$61.2M2025+11%
Operating income45672-$8.2M in 2025
-$40.0M-$20.0M0$20.0M2020: $7.9M$7.9M20202021: -$34.9M-$34.9M20212022: -$27.5M-$27.5M2022−21%2023: -$2.1M-$2.1M2023−92%2024: -$13.7M-$13.7M2024+560%2025: -$8.2M-$8.2M2025−40%
Net income45672-$11.4M in 2025
-$60.0M-$40.0M-$20.0M0$20.0M2020: $5.3M$5.3M20202021: -$44.0M-$44.0M20212022: -$29.6M-$29.6M2022−33%2023: -$3.9M-$3.9M2023−87%2024: -$14.7M-$14.7M2024+281%2025: -$11.4M-$11.4M2025−22%

Every line of the income statement as filed: the last 2 fiscal years, latest first.2

Period ending2025-12-312024-12-31
Product revenue, net$61.2M$55.1M
Other revenue$619.0K$1.0M
Total revenue$61.9M$56.1M
Cost of goods sold - (excluding amortization of acquired intangible assets)$20.9M$20.9M
Amortization of acquired intangible assets$4.3M$3.4M
Research and development$480.0K$9.9M
Selling, general and administrative$44.4M$40.2M
Loss recovery-$4.6M
Total operating expenses$70.0M$69.8M
Loss from operations-$8.2M-$13.7M
Interest income-$589.0K-$757.0K
Interest expense$3.7M$2.7M
Gain on extinguishment of debt-$1.1M
Foreign exchange transaction losses$90.0K$116.0K
Total other expense$3.2M$934.0K
Loss before income taxes-$11.4M-$14.6M
Income tax expense$60.0K$61.0K
Net loss-$11.4M-$14.7M
Basic (In dollars per share)-$0.47-$0.72
Diluted (In dollars per share)-$0.47-$0.72
Basic (In shares)24.5M shares20.4M shares
Diluted (In shares)24.5M shares20.4M shares

Compare Journey Medical Corp with another company

Leadership

Who has led Journey Medical Corp, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Claude Maraoui2021–now

President

  1. Claude Maraoui2021–now

Chief financial officer

  1. Paolantonio Ernest Robert De2021–2022
  2. Joseph Benesch2023–now

Chief operating officer

  1. Ramsey Alloush2025–now
2025
Board members and other officers (8)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Serves as Interim Chief Financial OfficerRobyn Hunter named Oct 5, 202123
  • DirectorJustin Smith named Oct 5, 202123

Timeline

  1. Nov 26, 2021New chief executive Claude Maraoui becomes CEO12

Filings

222 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 48 major events, 88 insider forms, 12 large holders, 1 private raises, 53 other. The latest 20:

  1. Oct 9, 2026SCHEDULE 13G/A EDGAR
  2. Aug 12, 202610-Q EDGAR
  3. Aug 12, 20268-K EDGAR
  4. Jul 31, 2026SCHEDULE 13G/A EDGAR
  5. Jul 15, 2026SCHEDULE 13G/A EDGAR
  6. Jul 2, 20264 OWNERSHIP DOCUMENT EDGAR
  7. Jul 2, 20264 OWNERSHIP DOCUMENT EDGAR
  8. Jul 2, 20264 OWNERSHIP DOCUMENT EDGAR
  9. Jun 29, 20264 OWNERSHIP DOCUMENT EDGAR
  10. Jun 26, 20264 OWNERSHIP DOCUMENT EDGAR
  11. Jun 26, 20264 OWNERSHIP DOCUMENT EDGAR
  12. Jun 26, 20264 OWNERSHIP DOCUMENT EDGAR
  13. Jun 26, 20264 OWNERSHIP DOCUMENT EDGAR
  14. Jun 26, 20268-K EDGAR
  15. May 13, 202610-Q EDGAR
  16. May 13, 20268-K EDGAR
  17. Apr 30, 2026SCHEDULE 13G EDGAR
  18. Apr 30, 2026DEFA14A EDGAR
  19. Apr 30, 2026DEF 14A EDGAR
  20. Apr 24, 20264 OWNERSHIP DOCUMENT EDGAR

The 222 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

32 open-market trades by officers, directors and large owners since October 2021: 9 buys and 23 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 2, 2025Maraoui ClaudePresident & CEOSale4,834$6.84$33.1KForm 4
May 2, 2025Benesch JosephCFOSale2,409$6.84$16.5KForm 4
May 2, 2025Alloush RamseyChief Operating OfficerSale2,857$6.84$19.5KForm 4
Mar 11, 2025Maraoui ClaudePresident & CEOSale49,271$5.01$246.8KForm 4
Mar 7, 2025Maraoui ClaudePresident & CEOSale14,905$5.01$74.7KForm 4
Mar 6, 2025Maraoui ClaudePresident & CEOSale25,551$5.04$128.8KForm 4
Mar 5, 2025Maraoui ClaudePresident & CEOSale18,147$5.13$93.1KForm 4
Mar 4, 2025Maraoui ClaudePresident & CEOSale28,901$5.04$145.7KForm 4
Mar 3, 2025Maraoui ClaudePresident & CEOSale23,508$5.19$122.0KForm 4
Feb 21, 2025Benesch JosephCFOSale1,365$5.19$7.1KForm 4
Aug 1, 2024Benesch JosephCFOSale9,324$5.47$51.0KForm 4
Jul 23, 2024Benesch JosephCFOSale4,055$5.40$21.9KForm 4
Mar 25, 2024ROSENWALD LINDSAY A MDDirectorBuy10,000$3.04$30.4KForm 4
Mar 22, 2024Maraoui ClaudePresident & CEOBuy10,000$3.48$34.8KForm 4
Mar 22, 2024Smith Justin AdamDirectorBuy30,000$3.47$104.1KForm 4
Mar 22, 2024ROSENWALD LINDSAY A MDDirectorBuy20,000$3.40$68.0KForm 4
Feb 22, 2024Benesch JosephCFOSale2,450$3.75$9.2KForm 4
Nov 28, 2023Paley JeffreyDirectorSale1,745$5.22$9.1KForm 4
Nov 8, 2023Paley JeffreyDirectorSale255$3.76$959Form 4
Nov 7, 2023Paley JeffreyDirectorSale2,245$3.48$7.8KForm 4

All 32 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Mar 31, 2021Raised $19 million in a private offering of equity Form D: $30 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 71. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Wasatch Advisors LP2,858,930$20.2M0.1%+725,560
Tang Capital Management LLC1,610,000$11.4M0.5%No change
Vanguard Capital Management LLC675,185$4.8M0.0%−406,895
Punch & Associates Investment Management, Inc.536,000$3.8M0.2%New
Pale Fire Capital SE528,584$3.7M0.3%+46,597
Opaleye Management Inc.350,000$2.5M0.2%−610,000
Summit Financial, LLC346,748$2.5M0.0%−33,059
Jane Street Group, LLC320,021$2.3M0.0%New
Diametric Capital, LP295,663$2.1M0.2%+99,251
Ikarian Capital, LLC251,436$1.8M0.3%No change
Renaissance Technologies LLC229,700$1.6M0.0%−12,800
Geode Capital Management, LLC216,004$1.5M0.0%−247,198
American Financial Group Inc180,000$1.3M0.4%No change
Trexquant Investment LP171,338$1.2M0.0%+143,242
Marshall Wace, Llp139,843$990.1K0.0%New
J. Goldman & Co LP137,584$974.1K0.0%−362,604
Millennium Management LLC110,016$778.9K0.0%−273,051
BlackRock, Inc.100,981$714.9K0.0%−871,881
XTX Topco Ltd100,923$714.5K0.0%+71,559
Vanguard Fiduciary Trust Co94,729$670.7K0.0%−42,977
Goldman Sachs Group Inc90,294$639.3K0.0%+20,905
UBS Group AG83,514$591.3K0.0%−306,624
Citadel Advisors LLC82,149$581.6K0.0%New
Pvg Asset Management Corp79,573$563.4K0.3%−190
Integrated Wealth Concepts LLC78,928$558.8K0.0%+38,559

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26